PolarityTE Inc. (PTE)

12.79 +0.68 (+5.615%)

IEX Real-Time Price

October 19, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 12.11

Price Open 12.37

Volume: 505,392

Avg Volume: 676,688

Market Cap: 274.67M

P/E Ratio -

52 Wk Range 11.9027-41.22





PTE Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-09-12
Q3 2018
BTO
0.00 (0)
-0.86
0.00

2018-06-14
Q2 2018
N/A
0.00 (0)
-1.47
0.00

2018-05-03
Q1 2018
N/A
0.00 (0)
0.00
0.00

News

PolarityTE takes issue with Citron post; shares down 16% (2018-10-18 14:40 SeekingAlpha)

In a statement , PolarityTE ( PTE -15.5% ) makes the usual short-sellers-are-evil assertions against Citron Research, calling its bearish reports "false and misleading." Key rebuttal points: More news on: PolarityTE, Inc., Healthcare stocks news, Stocks on the move, Read more …

 

Midday Gainers / Losers (10/18/2018) (2018-10-18 12:46 SeekingAlpha)

Gainers: PTI +312% . CCCL +136% . ECYT +51% . CNET +29% . CREG +27% . IFMK +24% . ORPN +24% . DXF +20% . ATAI +17% . YECO +20% . More news on: Proteostasis Therapeutics, China Ceramics Co., Ltd., Endocyte, Inc., Stocks on the move, , Top stock market news, …

 

PolarityTE Issues Statement on Misleading Internet Post (2018-10-18 12:29 PR Newswire)

SALT LAKE CITY , Oct. 18, 2018 /PRNewswire/ --PolarityTE, Inc. (Nasdaq: PTE), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the…

 

FDA deals blow to PolarityTE - Citron (2018-10-18 10:20 SeekingAlpha)

Andrew Left (Citron) takes note of a Form 483 letter the FDA sent to PolarityTE (NASDAQ: PTE ) in late September. Polarity, says Left, tried to hide this from investors, but a FOIA request to the FDA has made it available. More news on: PolarityTE, Inc., Healthcare stocks news, Stocks o…

 

PolarityTE® Announces Former Acelity Leader Sharon Whalen as Vice President of Market Access (2018-10-18 08:00 PR Newswire)

SALT LAKE CITY , Oct. 18, 2018 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of …

 


Statistics

Shares Outstanding: 21.48M

Top 15 Institution Percent: 48.40

Price To Sales: 602.01

Price To Book: 2.81

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -119.38

Return On Equity: 845.76

Profit Margin: N/A

Price History

Beta: 1.29

50-day Moving Avg: 21.06

200-day Moving Avg: 21.87

YTD Change: -44.27

5-day Change: -16.95

1-month Change: -25.68

3-month Change: -39.67

6-month Change: -27.04

1-year Change: -47.73

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: PolarityTE Inc.

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.polarityte.com

PolarityTE Inc is a commercial-stage biotechnology and regenerative biomaterials company. Its focused on transforming the lives of patients by discovering, designing and developing regenerative tissue products and biomaterials.